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the ovarian growing follicle pool
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Frauenklinik D€usseldorf, D€usseldorf, Germany; f GyneHealth Reproductive Health Group, Manchester, United Kingdom;
g Repromed, Dulwich, Australia; h Roche Diagnostics GmbH, Penzberg, Germany; and i Roche Diagnostics International
Ltd., Rotkreuz, SwitzerlandObjective: To evaluate a new fully automated assay measuring antim€ullerian hormone (AMH; Roche Elecsys) against antral follicle
count in women of reproductive age.
Design: Prospective cohort study.
Setting: Hospital infertility clinics and academic centers.
Patient(s): Four hundred ﬁfty-one women aged 18 to 44 years, with regular menstrual cycles.
Intervention(s): None.
Main Outcome Measure(s): AMH and antral follicle count (AFC) determined at a single visit on day 2–4 of the menstrual cycle.
Result(s): There was a statistically signiﬁcant variance in AFC but not in AMH between centers. Both AFC and AMH varied by age
(overall Spearman rho 0.50 for AFC and 0.47 for AMH), but there was also signiﬁcant between-center variation in the
relationship between AFC and age but not for AMH. There was a strong positive correlation between AMH and AFC (overall
spearman rho 0.68), which varied from 0.49 to 0.87 between centers. An agreement table using AFC cutoffs of 7 and 15 showed
classiﬁcation agreement in 63.2%, 56.9% and 74.5% of women for low, medium, and high groups, respectively.
Conclusion(s): The novel fully automated Elecsys AMH assay shows good correlations with age and AFC in women of reproductiveUse your smartphoneage, providing a reproducible measure of the growing follicle pool. (Fertil Steril 2015;103:
1074–80. 2015 by American Society for Reproductive Medicine.)
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1074P rediction of response andoutcome in assisted reproductionis a central aspect of current
practice, allowing greater individuali-
zation of treatment protocols, reducing
the risk of potentially serious adverse
effects such as ovarian hyperstimula-
tion syndrome (OHSS), and, at the other
end of the spectrum of response, identi-
fying poor responders and thus overall
providing more accurate information
to patients. The main approach to
such prediction is analysis of ovarianVOL. 103 NO. 4 / APRIL 2015
Fertility and Sterility®biomarkers that reﬂect follicular activity and thus the
response to gonadotropins during subsequent ovarian stimu-
lation. To achieve maturity during the time course of stimula-
tion, ovarian follicles must already be at the small antral stage
of development, so clinically valuable biomarkers will accu-
rately quantify the number of such growing follicles, often
termed the ovarian reserve. Although several biomarkers
have been investigated over the years (including follicle-
stimulating hormone [FSH], estradiol, and inhibin B), two
have shown markedly greater accuracy and are in widespread
use: antral follicle count (AFC) and antim€ullerian hormone
(AMH) (1–4). These have been extensively investigated in
women undergoing assisted conception but have much
broader application in women's health across the
reproductive life span.
Transvaginal ultrasound is used to determine AFC, iden-
tifying and counting the number of small antral follicles.
Developments in technology have improved image resolu-
tion, allowing follicles R2 mm to be readily visualized;
follicles up to 10 mm are generally included in the analysis.
The normal range is currently a matter of controversy (5).
Although prediction of pregnancy is poor, AFC shows
good prediction of the number of oocytes that will be
retrieved after stimulation (3, 6). Its immediacy and wide
availability are signiﬁcant advantages. However, although
automated determination of AFC is being developed and
protocols for standardization are described (7), it remains
an essentially subjective measure affected by the operator,
the equipment used, and the patient because factors such
as high body mass index (BMI) and pelvic pathology may
impact the result.
Measurement of circulating AMH also reﬂects the num-
ber of small antral follicles and is predictive of ovarian
response (1, 6). Although AMH is produced by the
granulosa cells of follicles from the earliest stages of growth
through the preantral and early antral stages, production
declines abruptly at the stage at which follicles are selected
for dominance, 8–10 mm (8). In normal women, the
population of follicles of 5–8 mm diameter produces most
circulating AMH (9). In comparison with AFC, AMH shows
good prediction of oocyte number and similarly limited
prediction of pregnancy and live birth (4, 6, 10). As a
biochemical test, there are potential advantages in
standardization and thus consistency in results both within
and between centers, but this has yet to be realized. The
currently available assays are manual, plate-based enzyme-
linked immunosorbent assays (ELISAs); although these have
led to a wealth of understanding of the value of AMH
measurement across a wide range of physiologic and clinical
situations (11), there are issues of lack of standardization
among those produced by different manufacturers and con-
cerns about data reliability (12).
Fully automated platform-based AMH assays are being
developed, with the characteristics of one developed by Roche
Diagnostics recently described (13). Our study was designed to
investigate the value of AMH measurement using this novel
Elecsys AMH assay in the assessment of ovarian reserve as
expressed by AFC.VOL. 103 NO. 4 / APRIL 2015MATERIALS AND METHODS
Study Design
Our prospective observational study, undertaken in seven
infertility centers, enrolled a subject cohort of healthy female
volunteers and patients and measured the AMH concentra-
tion in relation to the AFC determined via transvaginal
sonography on days 2–4 of a menstrual cycle. The women
were recruited from the general population and from infer-
tility clinics. In both cases, the inclusion criteria included
ages 18–44 years inclusive, regular self-reported menstrual
cycles from 24 to 35 days in length, and informed consent
given in writing. The exclusion criteria included pregnancy,
major uterine or ovarian abnormalities detected by transvagi-
nal sonography, polycystic ovary syndrome (PCOS), endo-
crine or metabolic abnormalities (i.e., diabetes type I or II,
or pituitary, adrenal, pancreas, liver, or kidney disturbances),
ovarian surgery in the past 6 months, hormone therapy in the
preceding 3months (hormonal contraceptives, gonadotropin-
releasing hormone [GnRH] agonists, FSH), or current or past
smoking. The sample size calculation was based on accurate
estimation of the Spearman correlation coefﬁcient as well
as on an accurate estimation of AMH cutoffs for the AFC
<7 and AFCR15 group.
We calculated that at least 400 patients should be enrolled
to obtain accurate estimates for the Spearman correlation co-
efﬁcient as well as AMH cutoffs. With this number of patients,
a preassumed correlation coefﬁcient of 0.6 can be estimated
with the width of its conﬁdence interval smaller than 0.2
(14). In addition, the assumed prevalences for the AFC %7,
AFC 8–15, AFC>15 groups were 10%, 40%, and 50%, result-
ing in the determination of the 10% and 50% quantile for
AMH cutoffs. With the determined sample size, the width of
the conﬁdence intervals (CI) of these cutoffs will be smaller
than 0.56 ng/mL. The study received ethics committee
approval in all centers.
The study intervention consisted of a single visit, at which
a blood sample was taken for later hormone measurements
and a transvaginal ultrasound examination was performed
to determine AFC. Antral follicles were classiﬁed as those
measuring 2–10 mm in diameter, and AFC was determined
as the overall number of antral follicles counted in both
ovaries. In all centers, AFC was determined by as few individ-
uals as possible, and a consistent methodology was followed
(7). In all centers, two-dimensional (2D) transvaginal ultra-
sound equipment with a probeR6 MHz, minimal resolution
2 mm was used (Supplemental Table 1, available online).
The sonographic evaluation of all study participants was per-
formed between January 2013 and January 2014.
Blood was allowed to clot, and the serum separated by
centrifugation and stored at 80C (or at 20C for a
maximum of 6 months) until analysis after shipping to a cen-
tral laboratory (Free University Brussels, Belgium). All serum
markers (AMH, FSH, E2) were determined in single measure-
ment on the e601-module of the fully automated cobas6000
system. The measurements were split over 10 independent
runs which were performed on different days. For each of
the markers, a two-level control sample set was determined1075
ORIGINAL ARTICLE: REPRODUCTIVE ENDOCRINOLOGYin each run (AMH 0.93 and 4.8 ng/mL, FSH 17.5 and 44.5
IU/L, and E2 368 and 1,999 pmol/L).
The new Elecsys AMH assay is a sandwich assay based on
electrochemiluminescence technology. The total duration of
the assay is 18 minutes, and the sample volume is 50 mL.
The assay is calibrated against the Beckman Coulter AMH
Gen II ELISA (unmodiﬁed version without predilution) assay
with a measuring range of 0.01–23 ng/mL. The limit of quan-
titation (functional sensitivity) is 0.03 ng/mL. The coefﬁcients
of variation as determined for the control samples during the
study measurements were %3.3%, %2.2%, and %3.7% for
the intermediate precision for AMH, FSH, and E2, respectively.
The statistical analysis was performed using R 3.0.1 software.
The inﬂuence of categorical covariables on the AMH or
AFC value was based on analysis of variance (ANOVA) F tests,
and box plots show the distribution of these values in the
different categories. Individual group comparisons were
based on the t test. The correlation between AMH or AFC
and other continuous variables as well as between AMH
and AFC was assessed via Spearman's rho correlation coefﬁ-
cient and tested whether this correlation coefﬁcient is
different from zero. The relationship between AFC and age,
as well AMH and age, is exempliﬁed by the Passing-Bablok
regression, a robust regression analysis. The agreement be-
tween AFC and AMH groups (low AFC group %7; middle
AFC group ¼ 8–15; high AFC group >15) (15, 16) is shown
in an agreement table, with absolute numbers as well as
percentages. Receiver-operator characteristic (ROC) curves
are used to show the classiﬁcation potential of AMH to iden-
tify low ovarian reserve and high ovarian reserve based on
AFC <7 and AFC >15, respectively. Sensitivity, speciﬁcity,
and Youden's index were calculated for the AMH quantiles
as derived for the agreement tables. For ROC curves, the
area under the curve (AUC) with its 95% conﬁdence interval
(CI) was calculated as well. For the combination of AMH
and age, a logistic regression model was used for the classiﬁ-
cation in low or high ovarian reserve.RESULTS
For our study, 487 eligible women met the inclusion and
exclusion criteria. From these women, 36 had to be excluded
because of sample-handling issues, so data from 451 women
were used for the statistical analysis, with the number of
women contributed by each site varying between 115 and
17. Their demographic characteristics are given in Table 1.
As for the participating women, 92% were Caucasian, their
mean age was 32.8 years (range: 18.0–44.0 years), their
mean BMI was 24.3 kg/m2 (range: 16.7–52.7), and 68.5%
were not infertile. Their ages were approximately evenly
distributed between groups aged 18–29, 30–34, and
35–39 years, with fewer aged 40–45 years.
To minimize interobserver variation, 91% of AFC deter-
minations were performed by 13 clinicians/sonographers.
The distribution of AFC and AMH values is shown in
Supplemental Table 2 (available online) overall and for each
site, together with FSH and E2 measurements. There were sta-
tistically signiﬁcant differences in mean AFC values among
the centers (P< .001) whereas the AMH mean values did not1076vary by center (P¼ .30). As expected, both AFC and AMH var-
ied by age (overall Spearman's rho 0.50 for AFC and 0.47
for AMH, P< .001; Fig. 1). There was also statistically signif-
icant between-center variation for age-adjusted AFC
(P< .001) but not for age-adjusted AMH (P¼ .19).
The primary aim of this study was to investigate AMH
(using the Elecsys AMH assay) as a biomarker of the ovarian
reserve determined by AFC. The study conﬁrmed that there is
a strong positive correlation between AMH and AFC (Spear-
man's rho ¼ 0.68, P< .001). This relationship was present in
each center (all P< .001; Supplemental Table 3, available on-
line), although Spearman's rho varied from 0.49 to 0.87.
As AFC is used clinically to deﬁne poor responders and
those at risk of OHSS, further analysis explored AMH by
AFC group using the AFC groupings of 0–7, 8–15, and >15
(15). This showed highly signiﬁcant differences in mean
AMH between the AFC groups (P< .001; Supplemental
Fig. 1, available online). An agreement table was constructed
using the same AFC cutoffs of 7 and 15, with an AFC of 7 cor-
responding to the 15th percentile and AFC of 15 to the 52nd
percentile. The equivalent percentiles for AMH were 0.68 ng/
mL and 2.27 ng/mL. This analysis (Table 2) shows classiﬁca-
tion agreement in 63.2%, 56.9%, and 74.5% of women for the
low, medium, and high groups, respectively.
We also analyzed AMH in comparison with FSH and E2
concentrations, with all samples being taken on days 2–4 of
the menstrual cycle. The FSH concentrations ranged from
0.51 to 45.9 IU/L and E2 from 18.4 to 684 pmol/L. There
was a negative relationship between AMH and FSH (Spear-
man's rho 0.42, P< .001) but no statistically signiﬁcant
relationship with E2 (Spearman's rho 0.04, P¼ .45).
The ROC curve analysis was performed for the classiﬁca-
tion of low AFC (%7), which included 66 women versus 385
with AFC >7 and high AFC >15 (216 women vs. 235 women
with lower AFC) (Fig. 2). For both low and high AFC classiﬁ-
cations, AMH showed good discrimination with AUC of
91.1% (95% CI, 87.1%–95.2%) and 82.7% (95% CI, 79.0%–
86.5%), respectively (both P< .001). This was statistically
signiﬁcantly better than for age, and markedly so than for
the hormones FSH and E2. The sensitivity and speciﬁcity
calculated for the classiﬁcation of low and high AFC by
means of the AMH quantiles as derived for the agreement ta-
bles were 65.2% and 93.5%, respectively, for the low AMH
quantile (0.68 ng/mL), and 74.5% and 76.2% for the high
AMH quantile (2.3 ng/mL). Youden's indices (sensitivity þ
speciﬁcity –1) were 0.59 and 0.51, respectively. The combina-
tion of AMH with age did not statistically signiﬁcantly
improve the clinical performance for the low and high AFC
classiﬁcations: AUC 91.7% (95% CI, 87.8%–95.6%) and
83.6% (95% CI, 80.0%–87.2%), respectively.DISCUSSION
This study shows the value of a novel fully automated Elecsys
AMH assay in the analysis of ovarian reserve as deﬁned by
AFC. Both AFC and AMH have become widely used bio-
markers for what is widely termed the ovarian reserve in the
context of prediction of assisted reproductive treatment
outcome, which is of key importance to patients and theirVOL. 103 NO. 4 / APRIL 2015
TABLE 1
Demographic characteristics of subjects included in the analysis, overall and by study site.
Characteristics Overall (N[ 451)
Site number
1 (n[ 37) 2 (n[ 55) 3 (n[ 59) 4 (n[ 111) 5 (n[ 57) 6 (n[ 115) 7 (n[ 17)
Age (y)
Mean (95% CI) 32.84 (32.31–33.38) 34.16 (32.54–35.79) 32.76 (31.43–34.10) 33.12 (32.15–34.08) 30.17 (28.89–31.45) 31.16 (29.79–32.53) 35.23 (34.25–36.21) 36.24 (33.67–38.80)
SD 5.78 4.87 4.94 3.7 6.82 5.16 5.31 4.99
Min–Max 18.00–44.00 25.00–44.00 21.00–42.00 26.00–40.00 18.00–44.00 22.00–42.00 21.00–44.00 23.00–43.00
Age group (y)
18–29 123 (27.27) 7 (18.92) 13 (23.64) 9 (15.25) 51 (45.95) 25 (43.86) 16 (13.91) 2 (11.76)
30–34 148 (32.82) 13 (35.14) 22 (40.00) 32 (54.24) 28 (25.23) 16 (28.07) 34 (29.57) 3 (17.65)
35–39 120 (26.61) 11 (29.73) 13 (23.64) 15 (25.42) 22 (19.82) 13 (22.81) 38 (33.04) 8 (47.06)
40–45 60 (13.30) 6 (16.22) 7 (12.73) 3 (5.08) 10 (9.01) 3 (5.26) 27 (23.48) 4 (23.53)
Race
White 414 (91.80) 32 (86.49) 46 (83.64) 55 (93.22) 109 (98.20) 47 (82.46) 110 (95.65) 15 (88.24)
Black 15 (3.33) 0 (0.00) 5 (9.09) 1 (1.69) 0 (0.00) 9 (15.79) 0 (0.00) 0 (0.00)
Asian 16 (3.55) 5 (13.51) 0 (0.00) 3 (5.08) 0 (0.00) 1 (1.75) 5 (4.35) 2 (11.76)
Other 6 (1.33) 0 (0.00) 4 (7.27) 0 (0.00) 2 (1.80) 0 (0.00) 0 (0.00) 0 (0.00)
Smoking habit
Current 99 (21.95) 3 (8.11) 8 (14.55) 8 (13.56) 52 (46.85) 16 (28.07) 11 (9.57) 1 (5.88)
Past 80 (17.74) 6 (16.22) 13 (23.64) 2 (3.39) 8 (7.21) 11 (19.30) 34 (29.57) 6 (35.29)
Never 272 (60.31) 28 (75.68) 34 (61.82) 49 (83.05) 51 (45.95) 30 (52.63) 70 (60.87) 10 (58.82)
Female infertility
No 309 (68.51) 20 (54.05) 28 (50.91) 27 (45.76) 90 (81.08) 30 (52.63) 109 (94.78) 5 (29.41)
Yes 142 (31.49) 17 (45.95) 27 (49.09) 32 (54.24) 21 (18.92) 27 (47.37) 6 (5.22) 12 (70.59)
BMI
Mean (95% CI) 24.30 (23.86–24.74) 25.72 (23.74–27.69) 24.03 (22.61–25.45) 22.88 (21.97–23.79) 23.07 (22.46–23.69) 25.32 (23.78–26.87) 25.46 (24.53–26.38) 23.84 (21.88–25.81)
SD 4.77 5.91 5.27 3.49 3.28 5.82 5.02 3.82
Min–Max 16.70–52.70 16.70–40.40 17.70–52.70 18.20–34.10 17.80–33.50 17.70–41.00 17.80–47.30 18.20–33.50
Note: Percentage of total in parentheses. CI ¼ conﬁdence interval; SD ¼ standard deviation.
Anderson. Automated AMH assay in ovarian assessment. Fertil Steril 2015.
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FIGURE 1
The relationships between (A) AFC and (B) AMH with age, with data from each site shown separately in different colors. To get a more structured
view of this data among the different centers, the robust Passing-Bablok regression was chosen to exemplify the mean relationship within each
center in this plot. Site-speciﬁc AFC/AMH and age distributions are shown in the box and whiskers plots, where the lower and upper limits of
the boxes show the lower and upper quartile, the line within the box the median, and the whiskers up to 1.5 times the interquartile range.
Anderson. Automated AMH assay in ovarian assessment. Fertil Steril 2015.
ORIGINAL ARTICLE: REPRODUCTIVE ENDOCRINOLOGYclinical teams. Although live birth is the ultimate positive
outcome, prediction of ovarian response is also of great value
for identifying women who are likely to respond poorly, thus
allowing appropriate counseling in advance, and for identi-
fying women likely to show an excessive response, thus pre-
dicting a potential for OHSS. Thus, in both groups
management strategies can be tailored to optimize outcome
and minimize risk (4).
Both AFC and AMH have speciﬁc characteristics and thus
advantages and disadvantages as biomarkers. Because AFC is
widely available, it has the advantage of immediacy, but stan-
dardization is a difﬁculty. Ultrasound equipment varies
among centers, and there have been progressive increases in
resolution and thus image quality over recent years. This
has led to substantial changes in what is regarded as a
‘‘normal’’ AFC, as well as in what might be used as a diag-TABLE 2
Agreement table for antral follicle count (AFC) groups and new
deﬁned antim€ullerian hormone (AMH) groups.
AMH group AFC 0–7 AFC 8–15 AFC>15 N
AMH% 0.681 43 (63.2%) 22 (32.4%) 3 (4.4%) 68
0.681 < AMH% 2.27 20 (12.0%) 95 (56.9%) 52 (31.1%) 167
AMH > 2.27 3 (1.4%) 52 (24.1%) 161 (74.5%) 216
N 66 169 216 451
Note: Percentages refer to AMH group numbers (AMH values in ng/mL).
Anderson. Automated AMH assay in ovarian assessment. Fertil Steril 2015.
1078nostic criterion in, for example, polycystic ovarian syndrome
(5). There is also well-recognized, substantial interobserver
variation (17), compounding the variations among women
and across the menstrual cycle (18); as a result, assessment
in the early follicular phase is required, as performed in this
study. Although AMH may show less intraindividual and
interindividual variation than AFC (19–21), the lack of
standardization of the calibrators among the different
manufacturers is also a signiﬁcant issue, as are other
methodologic problems that have affected reproducibility
(12). Previous assays have also all been manual plate-based
formats, with inherent susceptibility to variation within and
between laboratories and in lot-to-lot variation. The technical
characteristics of the fully automated AMH assay used in this
study have been recently described, indicating that it may
address many of the issues with the measurement of this
hormone (13, 22).
The present hormone analyses were all performed in a
single academic laboratory, with a very similar technical per-
formance for AMH to that previously described. There was no
signiﬁcant variation in AMH distribution between centers,
although there was signiﬁcant variation in AFC. Likewise,
although both AMH and AFC showed the expected inverse
relationship with age, there was signiﬁcant variation in that
relationship among centers for AFC but not for AMH. These
analyses may indicate that AMH measured by this new assay
is a more reliable indicator of the ovarian reserve than AFC.
The full automation of the AMH assay removes operator-
related variation; the centralization of hormone analysisVOL. 103 NO. 4 / APRIL 2015
FIGURE 2
ROC curves for classiﬁcation of (A) low AFC and (B) high AFC, by AMH, FSH, E2 and age. For low AFC, n ¼ 66 patients with AFC%7 versus 385
subjects AFC >7. For high AFC, n ¼ 216 subjects with AFC >15 versus 235 patients AFC%15.
Anderson. Automated AMH assay in ovarian assessment. Fertil Steril 2015.
Fertility and Sterility®removes a further source of variability, and thus this may not
exactly reﬂect the situation where individual sites perform
hormone analysis. The possibility of centralization is an
inherent advantage of hormone analysis over ultrasound-
based analysis: recording images and their ofﬂine and
centralized analysis are possible in principle (17), but they
are very time consuming, so one of the key advantages of
AFC, its immediacy, is lost.
Although AMH and AFC are sometimes regarded as inter-
changeable, there are emerging data suggesting that AMH is a
more reproducible measure of the ovarian response to stimu-
lation. In an analysis of potential markers to predict ovarian
response in a randomized controlled trial, AFC was not found
to be predictive (23). In contrast, AMH was predictive both of
number of retrieved oocytes and of poor versus excessive
response. Similarly, in another randomized controlled trial,
AMH but not AFC predicted oocyte yield after ovarian stimu-
lation (24). These ﬁndings have led to discussion of the limi-
tations of AFC for the prediction of ovarian response,
particularly in multicenter trials (25). Although the present
data do not include assessment of ovarian response, the
ﬁnding of signiﬁcant intercenter variability in the relation-
ship between AFC and age but not between AMH and age is
consistent with this growing recognition of difﬁculties in
standardizing AFC assessment among centers.
Further characterization of the relationship between AFC
and AMH showed good performance in an agreement table
and in ROC analyses. These results are similar to those previ-
ously reported using other AMH assays (4, 6) and support the
value of AMH across the dynamic range found in women of
ages across the reproductive life span.VOL. 103 NO. 4 / APRIL 2015In conclusion, these data demonstrate the clinical perfor-
mance of the new fully automated Elecsys AMH assay in the
analysis of the ovarian reserve in women of reproductive age.
The expected relationships with age and AFC were observed,
with evidence of much lower variability in the determination
of AMH compared with AFC. This supports the use of the
automated AMH assay in a range of contexts in reproductive
medicine such as in physiologic, therapeutic, and potentially
pathologic investigations.REFERENCES
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SUPPLEMENTAL FIGURE 1
Distribution of AMH (ng/mL) in different AFC groups for all sites. The P
values in the graph refer to t tests of AMH means between the AFC
0–7 and 8–15 group and between the 8–15 and >15 group.
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SUPPLEMENTAL TABLE 1
Characteristics of ultrasonography equipment used for transvaginal sonography at study sites.
Equipment
Study site
1 2 3 4 5 6 7
Manufacturer GE Siemens Toshiba GE GE Toshiba GE
Device type LOGIQ P3 Acuson X300 Nemio XG Voluson 730 ProV Voluson E8 Nemio XG Mk2 Voluson S8
Year of manufacture 2009 2008 2011 2005 2010 2008 2012
Probe frequency 8 MHz 4–9 MHz 7.5 MHz 3.7–9.3 MHz 4–8 MHz 6 MHz 8 MHz
Probe resolution 2 mm 2 mm < 2 mm 2 mm 1 mm 1 mm 2 mm
Yearly maintenance Yes Yes Yes Yes Yes Yes Yes
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SUPPLEMENTAL TABLE 2
Antral follicle count (AFC), antim€ullerian hormone (AMH), follicle-stimulating hormone (FSH), and estradiol (E2) data in study participants, overall and by study site.
Overall (N[ 451)
Site number
1 (n[ 37) 2 (n[ 55) 3 (n[ 59) 4 (n[ 111) 5 (n[ 57) 6 (n[ 115) 7 (n[ 17)
AFC group
0–7 66 (14.63) 5 (13.51) 13 (23.64) 10 (16.95) 20 (18.02) 2 (3.51) 12 (10.43) 4 (23.53)
8–15 169 (37.47) 7 (18.92) 18 (32.73) 32 (54.24) 34 (30.63) 18 (31.58) 49 (42.61) 11 (64.71)
>15 216 (47.89) 25 (67.57) 24 (43.64) 17 (28.81) 57 (51.35) 37 (64.91) 54 (46.96) 2 (11.76)
AFC [n]
Mean (95% CI) 16.17 (15.37–16.96) 19.03 (16.06–22.00) 15.31 (12.85–17.77) 13.39 (11.42–15.36) 15.63 (14.20–17.06) 21.30 (18.39–24.21) 16.02 (14.69–17.35) 9.71 (7.12–12.29)
SD 8.58 8.91 9.1 7.55 7.62 10.96 7.2 5.02
Min–Max 0.00–56.00 4.00–38.00 0.00–35.00 2.00–38.00 2.00–30.00 3.00–56.00 2.00–38.00 1.00–22.00
AMH [ng/mL]
Mean (95% CI) 2.64 (2.44–2.85) 2.68 (2.06–3.30) 2.27 (1.72–2.83) 3.01 (2.53–3.49) 2.65 (2.25–3.05) 2.12 (1.72–2.52) 2.86 (2.34–3.39) 2.74 (1.31–4.35)
SD 2.26 1.86 2.06 1.83 2.14 1.51 2.84 3.13
Min–Max 0.01–17.02 0.02–6.79 0.01–10.68 0.29–8.36 0.10–11.08 0.05–6.79 0.01–17.02 0.21–13.99
FSH [IU/L]
Mean (95% CI) 7.44 (7.10–7.79) 8.21 (5.85–10.57) 8.01 (6.97–9.06) 6.98 (6.49–7.46) 7.43 (6.84–8.03) 7.56 (6.39–8.73) 7.18 (6.65–7.71) 7.01 (4.81–9.22)
SD 3.74 7.08 3.83 1.85 3.17 4.42 2.85 4.3
Min–Max 0.51–45.94 3.75–45.94 3.81–26.00 3.67–14.35 1.37–22.21 4.34–36.38 0.51–18.61 0.68–22.32
E2 [pmol/L]
Mean (95% CI) 158 (150–165) 145 (120–169) 166 (145–187) 156 (137–175) 153 (135–171) 158 (138–178) 156 (142–170) 204 (127–282)
SD 84.34 72.86 77.7 71.76 94.76 75.18 76.61 150.25
Min–Max 18.35–684 18.35–354 56.59–396 62.32–348 18.35–684 52.44–461 30.17–631 26.31–655
Note: Percentage of total in parentheses. CI ¼ conﬁdence interval; SD ¼ standard deviation.
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SUPPLEMENTAL TABLE 3
Correlation between AFC and AMH over all sites and for individual sites.
Correlation All Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 Site 7
Spearman 0.68 0.71 0.86 0.49 0.87 0.74 0.62 0.75
P value (Spearman) < .001 < .001 < .001 < .001 < .001 < .001 < .001 < .001
Intercept 0.25 0.51 0.27 0.22 0.64 0.29 0.76 1.32
Slope 0.16 0.14 0.16 0.20 0.20 0.11 0.21 0.36
N 451 37 55 59 111 57 115 17
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